Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Presbyterian, M2, C-Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Liver Transplantation, The Thomas Starzl Transplant Institute, UPMC Montefiore, Room N758.1, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
Clin Liver Dis. 2016 May;20(2):351-64. doi: 10.1016/j.cld.2015.10.009. Epub 2016 Feb 19.
Weight loss, regular exercise, and diet composition modification seem to improve biochemical and histologic abnormalities. Other therapies directed at insulin resistance, oxidative stress, cytoprotection, and fibrosis may also offer benefits. Insulin sensitizers and vitamin E seem to be the most promising; however, they cause side effects. A multifaceted approach of lifestyle modifications, weight loss, and pharmacotherapy can be used in combination, but no single treatment approach has proved universally applicable to the general population with nonalcoholic steatohepatitis (NASH). Continuous clinical and preclinical studies on existing and potential drugs are needed to improve treatment of nonalcoholic fatty liver disease/NASH.
体重减轻、规律运动和饮食组成的调整似乎可以改善生化和组织学异常。其他针对胰岛素抵抗、氧化应激、细胞保护和纤维化的治疗方法也可能有益。胰岛素增敏剂和维生素 E 似乎最有希望，但它们也会引起副作用。生活方式改变、减肥和药物治疗的多方面方法可以联合使用，但没有单一的治疗方法被证明对非酒精性脂肪性肝炎（NASH）的一般人群普遍适用。需要对现有和潜在药物进行持续的临床和临床前研究，以改善非酒精性脂肪肝/ NASH 的治疗。
